# Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

Source: https://onco.cc/trials/nct06107374/  
OnCo record `nct06107374` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of [18F]F-AraG in non-small-cell lung cancer, run by CellSight Technologies, Inc., now recruiting.

## Summary

Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG is a phase 2 interventional study registered as NCT06107374 by CellSight Technologies, Inc., with 20 participants planned, started 2023-11-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: [18F]F-AraG.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06107374
- Phase: 2
- Setting: Imaging of T-cell Activation With [18F]F-araG in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1/PD-L1 Directed Therapy
- Sponsor: CellSight Technologies, Inc.
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06107374: https://clinicaltrials.gov/study/NCT06107374

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct06107374.json